The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial loss in body size and enhance metabolic health, particula